KIF20A and biliary tract neoplasm: The studies by Ryuji Okuyama et al. and Atsushi Aruga et al., demonstrating the tolerability and immunogenicity of KIF20A-targeting peptide vaccines, indicate a promising avenue for stable disease management in advanced pancreatic and biliary tract cancers [95,96].